항암제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Anticancer Drugs Market size is expected to reach USD 453.42 Billion in 2034 from USD 201.83 Billion (2025) growing at a CAGR of 9.41% during 2026-2034.

The global anticancer drugs market is witnessing strong growth due to the rising global cancer burden and increasing awareness about early diagnosis and treatment. The growing prevalence of breast cancer, lung cancer, colorectal cancer, and other malignancies is significantly driving demand for effective therapies. Pharmaceutical companies are investing heavily in oncology research to develop advanced and targeted treatment options.

The market is primarily driven by advancements in immunotherapy, targeted therapy, and precision medicine. Increasing clinical trials, regulatory approvals, and strong pipelines of innovative drugs are accelerating market expansion. Supportive government initiatives, improved healthcare infrastructure, and rising healthcare spending in both developed and developing countries are further strengthening growth. Additionally, the introduction of biosimilars is improving affordability and accessibility.

In the coming years, personalized medicine and combination therapies are expected to dominate the oncology landscape. Advances in biotechnology and molecular diagnostics will continue to support drug development. With increasing investments and ongoing research, the anticancer drugs market is projected to maintain robust growth and expand significantly across global healthcare systems.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Type

• Cytotoxic Drugs (Alkylating Agents, Antimetabolites, Others)
• Targeted Drugs (Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Others)
• Hormonal Drugs

By Therapy Type

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Others

By Cancer Type

• Lung Cancer
• Breast Cancer
• Leukemia
• Colorectal Cancer
• Others

COMPANIES PROFILED

• Amgen Inc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, F HoffmannLa Roche Ltd, Novartis AG, Pfizer Inc, Bayer AG, Merck Co Inc, AstraZeneca plc, Celgene Corporation
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTICANCER DRUGS MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Cytotoxic Drugs (Alkylating Agents, Antimetabolites, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Targeted Drugs (Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Hormonal Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTICANCER DRUGS MARKET: BY THERAPY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Therapy Type
• 5.2. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTICANCER DRUGS MARKET: BY CANCER TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Cancer Type
• 6.2. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTICANCER DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Type
  • 7.2.2 By Therapy Type
  • 7.2.3 By Cancer Type
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Type
  • 7.3.2 By Therapy Type
  • 7.3.3 By Cancer Type
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Type
  • 7.4.2 By Therapy Type
  • 7.4.3 By Cancer Type
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Type
  • 7.5.2 By Therapy Type
  • 7.5.3 By Cancer Type
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Type
  • 7.6.2 By Therapy Type
  • 7.6.3 By Cancer Type
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ANTICANCER DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Amgen Inc
  • 9.2.2 Takeda Pharmaceutical Company Limited
  • 9.2.3 Eli Lilly And Company
  • 9.2.4 F. Hoffmann-La Roche Ltd
  • 9.2.5 Novartis AG
  • 9.2.6 Pfizer Inc
  • 9.2.7 Bayer AG
  • 9.2.8 Merck & Co. Inc
  • 9.2.9 AstraZeneca Plc
  • 9.2.10 Celgene Corporation